Vol. 6 (01) pp. 1581-1590 DOI: 10.21474/IJAR01/6393

THERAPEUTIC APPLICATIONS OF VEGF INHIBITORS IN BREAST CANCER.

, and
  • Department of surgical oncology, Faculty of Medicine, University of Tabuk, Kingdom of Saudi Arabia.
  • Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk, Kingdom of Saudi Arabia, Tabuk
  • Prince Sultan Oncology Center, King Salman Armed Force Hospital, Tabuk, Saudi Arabia.
14 Downloads 98 Views
Crossref

Download Full Paper (PDF)

Abstract

The importance of angiogenesis in tumour growth and development is well known. Angiogenesis is implicated in the pathogenesis of malignancy and metastasis. The overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in cancer. Recently the inhibition of angiogenesis has demonstrated clinically significant improvements in outcomes in a variety of malignancies, including breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in advanced solid tumours, such breast, colorectal, lung and renal cancer. Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications. The humanized monoclonal antibody against VEGF, bevacizumab, is the clinically most mature of the antiangiogenic agents and has recently been shown to improve outcome when combined with chemotherapy in the first-line metastatic setting of breast cancer. Different antiangiogenic agents are currently under investigation, including drugs that inhibit the VEGF receptor 2, the cognate receptor for VEGF found on endothelial cells. The combination of antiangiogenic drugs with one another and with other biologic agents is also being explored in an attempt to improve efficacy and to overcome the drug resistance seen with the initial studies of antiangiogenic agents.

Keywords

Article Analytics

References

  1. Sheikh A, Hussain SA, Ghori Q, Naeem N, Fazil A, Giri S, Sathian B, Mainali P,Al Tamimi DM. The spectrum of genetic mutations in breast cancer. Asian Pac J Cancer Prev. 2015;16(6):2177-85.
  2. Kleibl Z, Kristensen VN Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management..Breast. 2016 Aug; 28:136-44.
  3. Kota K, Brufsky A, Oesterreich S, Lee A. Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. Cureus.2017 Jul 6;9(7):e1434.
  4. Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2017;17(2):152-163.
  5. Farsinejad S, Rahaie M, Alizadeh AM, Mir-Derikvand M, Gheisary Z, Nosrati H,Khalighfard S. Expression of the circulating and the tissue microRNAs after surgery, chemotherapy, and radiotherapy in mice mammary tumor. Tumour Biol. 2016 Oct;37(10):14225-14234.
  6. Fletcher CE, Dart DA, Bevan CL. Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers. Endocr Relat Cancer. 2014 Oct;21(5):R409-29.
  7. Sang Y, Tang J, Li S, Li L, Tang X, Cheng C, Luo Y, Qian X, Deng LM, Liu L, Lv XB. LncRNA PANDAR regulates the G1/S transition of breast cancer cells by suppressing p16(INK4A) expression. Sci Rep. 2016 Mar 1;6:22366
  8. Li J, Chen Y, Chen Z, He A, Xie H, Zhang Q, Cai Z, Liu Y, Huang W. SPRY4-IT1: A novel oncogenic long non-coding RNA in human cancers. Tumour Biol. 2017 Jun;39(6):1010428317711406.
  9. Gupta R. A.?et al.Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.?Nature?464, 1071?1076, 10.1038/nature08975 (2010).
  10. Senger, DR; Galli, SJ; Dvorak, AM; Perruzzi, CA; Harvey, VS; Dvorak, HF (25 February 1983).?"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.".?Science.?219?(4587): 983?5
  11. Ferrara, N; Henzel, WJ (15 June 1989).?"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.".?Biochemical and Biophysical Research Communications.?161?(2): 851?8
  12. Tischer, E; Mitchell, R; Hartman, T; Silva, M; Gospodarowicz, D; Fiddes, JC; Abraham, JA (25 June 1991).?"The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.".?The Journal of Biological Chemistry.?266?(18): 11947?54
  13. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M .Angiogenesis in cancer.Vasc Health Risk Manag. 2006; 2(3):213-9.
  14. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies.?Angiogenesis.?2002;5:237?256.
  15. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.?J Clin Invest.?2006;116:2610?2621
  16. Niu G., Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.?Curr. Drug Targets.?2010;11:1000?1017.
  17. Grothey A., Ellis L.M. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.?Cancer J.?2008;14:170?177
  18. C?be Suarez, S; Pieren, M; Cariolato, L; Arn, S; Hoffmann, U; Bogucki, A; Manlius, C; Wood, J; Ballmer-Hofer, K. "A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2".?Cellular and Molecular Life Sciences.?63: 2067?2077
  19. Shin, Y. J.; Choi, J. S.; et al. (2010). "Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats".?J Neuroimmunol.?229?(1?2): 81?90.
  20. LeCouter J, Lin R, Ferrara N.The role of EG-VEGF in the regulation of angiogenesis in endocrine glands.Cold Spring Harb Symp Quant Biol. 2002; 67():217-21.
  21. Keramidas M, Faudot C, Cibiel A, Feige JJ, Thomas M.Mitogenic functions of endocrine gland-derived vascular endothelial growth factor and Bombina variegata 8 on steroidogenic adrenocortical cells.J Endocrinol. 2008 Mar; 196(3):473-82.
  22. Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J. (2007). "Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition".?Cellular Signalling.?19(10): 2003?12.
  23. Herzog, B; Pellet-Many, C; Britton, G; Hartzoulakis, B; Zachary, I. C. (2011).?"VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation".?Molecular Biology of the Cell.?22(15): 2766?2776
  24. Oltmanns, K. M.; Gehring, H; Rudolf, S; Schultes, B; Hackenberg, C; Schweiger, U; Born, J; Fehm, H. L.; Peters, A (2006). "Acute hypoxia decreases plasma VEGF concentration in healthy humans".?AJP: Endocrinology and Metabolism.?290(3): E434?9.
  25. Schlessinger, J. and Lemmon, M. A. Sh2 And Ptb domains in tyrosine kinase signaling. Sci. STKE .2003 191, RE12.
  26. Wiesmann, C., Muller, Y. A., and de Vos, A. M. Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. J. Mol. Med. 2000, 78, 247?260.
  27. Blechman, J. M., Lev, S., Brizzi, M. F., Leitner, O., Pegoraro, L., Givol, D., and Yarden, Y. Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. J. Biol. Chem. 1993, 268, 4399?4406. 47.
  28. Blechman, J. M. and Yarden, Y. Structural aspects of receptor dimerization. c-kit as an example. Ann. N Y Acad. Sci. 1995, 766, 344?362.
  29. Herren, B., Rooney, B., Weyer, K. A., Iberg, N., Schmid, G., and Pech, M. (1993) Dimerization of extracellular domains of platelet-derived growth factor receptors. A revised model of receptor-ligand interaction. J. Biol. Chem. 268, 15088?15095. 49.
  30. Fuh, G., Li, B., Crowley, C., Cunningham, B., and Wells, J. A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197? 11204
  31. Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N,Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A. Angiogenesis Inhibitors in NSCLC. Int J Mol Sci. 2017 Sep 21;18(10). pii: E2021.
  32. Jennifer Couzin-Frankel; Yasmin Ogale (8 July 2011). "Once on 'Fast Track', Avastin Now Derailed".?Science.?333?(6039): 143?4.
  33. Larsen FO, Markussen A, Diness LV, Nielsen D. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. Oncology. 2017 Sep 21
  34. Ntavatzikos A, Spathis A, Patapis P, Machairas N, Peros G, Konstantoudakis S, Leventakou D, Panayiotides IG, Karakitsos P, Koumarianou A. Integrating TYMS,KRAS and BRAF testing in patients with metastatic colorectal cancer. World J Gastroenterol. 2017 Aug 28;23(32):5913-5924.
  35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.?N Engl J Med.?2004;350:2335?2342
  36. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel?carboplatin alone or with bevacizumab for non-small-cell lung cancer.?N Engl J Med.?2006;355:2542?2550.
  37. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy.?Oncology.?2005;69?Suppl 3:25?33.
  38. Li C1,?Xiang A2,?Chen X3,?Yin K4,?Lu J4,?Yin W5,6.Optimizing the treatment of?bevacizumab?as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced?breast cancer: an updated meta-analysis of published randomized trials.Onco Targets Ther.2017 Jun 27;10:3155-3168.
  39. US Food and Drug Administration(2006).?"FDA approves new treatment for gastrointestinal and kidney cancer".
  40. Hartmann JT, Kanz L (November 2008).?"Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition".?Arch Dermatol.?144?(11): 1525?6.
  41. Quek R, George S (February 2009). "Gastrointestinal stromal tumor: a clinical overview".?Hematol. Oncol. Clin. North Am.?23?(1): 69?78
  42. "Prescribing information for Sutent (sunitinib malate)".?Pfizer, Inc, New York NY.
  43. Gradishar W.J. Sorafenib in locally advanced or metastatic breast cancer.?Expert Opin. Investig. Drugs.?2012;21:1177?1191.
  44. Schwartzberg L.S., Tauer K.W., Hermann R.C., Makari-Judson G., Isaacs C., Beck J.T., Kaklamani V., Stepanski E.J., Rugo H.S., Wang W., et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with her-2-negative advanced breast cancer that progressed during or after bevacizumab.?Clin. Cancer Res.?2013;19:2745?2754.
  45. Keating GM, Santoro A (2009). "Sorafenib: a review of its use in advanced hepatocellular carcinoma".?Drugs.? 69?(2): 223?40
  46. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (October 2008). "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling".? Cancer Ther.?7(10): 3129?40.
  47. Choueiri T.K., Mayer E.L., Je Y., Rosenberg J.E., Nguyen P.L., Azzi G.R., Bellmunt J., Burstein H.J., Schutz F.A. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.?J. Clin. Oncol.?2011;29:632?638.
  48. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., Leong S., O?Bryant C., Chow L.Q., Serkova N.J., et al. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin g1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.?J. Clin. Oncol.?2010;28:780?787.
  49. Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer. [(accessed on 1 December 2014)];?Available online:?http://clinicaltrials.gov/ct2/show/NCT00703326.

How to Cite This Article

Ibrahim Abdullah Al Balawi, Rashid Mir and Ebtesam Hamoud. (2018); THERAPEUTIC APPLICATIONS OF VEGF INHIBITORS IN BREAST CANCER., Int. J. of Adv. Res., 6 (01), 1581-1590, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/6393

Corresponding Author

DR RASHID MIR
Assistant Professor, Department of Medical Lab Technology, Faculty of Applied Medical Sciences.
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.